Florent Dumezy

Lille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Multicenter Flow Cytometry For Acute Myeloid Leukemia Measurable Residual Disease With LAIP/DfN And CD34+CD38- Leukemic Stem Cell-Enriched Populations.

Multicenter Flow Cytometry For Acute Myeloid Leukemia Measurable Residual Disease With LAIP/DfN And CD34+CD38- Leukemic Stem Cell-Enriched Populations.

Journal: Journal of visualized experiments : JoVE

Published: August 10, 2026

Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.

Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.

Journal: British journal of haematology

Published: June 19, 2025

NPM1 mutation subtype switch in acute myeloid leukemia.

NPM1 mutation subtype switch in acute myeloid leukemia.

Journal: Haematologica

Published: November 06, 2024

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.

Journal: Leukemia

Published: February 22, 2024

Oligomonocytic chronic myelomonocytic leukemia is eligible to MDS-score and not Mono-dysplasia score.

Oligomonocytic chronic myelomonocytic leukemia is eligible to MDS-score and not Mono-dysplasia score.

Journal: International journal of laboratory hematology

Published: February 20, 2024

A new combination of monocytic scores to support diagnosis of chronic myelomonocytic leukemia according to novel classifications.

A new combination of monocytic scores to support diagnosis of chronic myelomonocytic leukemia according to novel classifications.

Journal: International journal of laboratory hematology

Published: January 06, 2023

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.

Journal: Leukemia

Published: November 04, 2019

B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.

B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.

Journal: Frontiers in oncology

Published: September 01, 2019

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.

Journal: Leukemia & lymphoma

Published: January 09, 2019

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation.

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation.

Journal: Journal of visualized experiments : JoVE

Published: November 20, 2018

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.

Journal: Cancer medicine

Published: October 04, 2018

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.

Journal: Leukemia

Published: July 14, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026